上海凯宝：KBZ24020获得《药物临床试验批准通知书》

Group 1 - Shanghai Kaibao announced the approval of clinical trial for drug KBZ24020, classified as Traditional Chinese Medicine 1.1 [1] - The clinical trial is aimed at treating acute ischemic stroke and is set to proceed after further refinement of the trial protocol [1] - The company's revenue composition for 2024 is reported as 99.87% from industrial operations and 0.13% from other businesses [1] Group 2 - As of the latest report, Shanghai Kaibao has a market capitalization of 6.8 billion yuan [2]